1. In Vivo
  2. >>Innovation

The Journey Has Just Begun For LAG-3 Therapeutics

 
• By Jo Shorthouse

Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.  

Journey
• Source: Shutterstock

Data from LAG-3 trials caused a stir at the 2021 ASCO meeting, with promising clinical data in this third class of checkpoint inhibitor presented by firms such as Regeneron Pharmaceuticals, Inc., Merck & Co., Inc. and – with a different approach - Immutep Ltd. (Also see "ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations" - Scrip, 7 June, 2021.)

In the year since, the FDA has approved Bristol Myers Squibb Company’s LAG-3 blocker relatlimab in a fixed-dose combination...

More from Innovation

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By Ashley Yeo

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo